Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15158228 | 1.00 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL4539668 | 1.00 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Water SCHEMBL489161 | 0.99 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL15158230 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL271324 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL2367515 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL2883494 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL1985230 | 0.85 | ADORA2A (0.64) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL3949118 | 0.84 | ADORA3 (0.72) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL18556282 | 0.84 | ADORA2A (0.80) | ADORA2AADORA3ADORA2BADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760637-A2 | STABLE SOLID FORMS OF REGADENOSON | AMRI Italy S.r.l. (IT) | 2021-01-06 | — | — | EP | claimed |
| EP-2789624-B1 | Stable solid forms of regadenoson | AMRI ITALY SRL (IT) | 2020-09-23 | — | — | EP | claimed |
| US-RE47351-E1 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | claimed |
| US-RE47301-E1 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | GILEAD SCIENCES, INC. (US) | 2019-03-19 | — | — | US | claimed |
| US-10144756-B2 | Stable solid forms of regadenoson | AMRI ITALY S.R.L. (IT) | 2018-12-04 | — | — | US | claimed |
| EP-1989214-B1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | GILEAD SCIENCES INC (US) | 2016-06-22 | — | — | EP | claimed |
| EP-2984099-A1 | STABLE SOLID FORMS OF REGADENOSON | Euticals S.P.A. (IT) | 2016-02-17 | — | — | EP | claimed |
| US-20160024137-A1 | STABLE SOLID FORMS OF REGADENOSON | AMRI ITALY S.R.L. (IT) | 2016-01-28 | — | — | US | claimed |
| US-9085601-B2 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | GILEAD SCIENCES, INC. (US) | 2015-07-21 | — | — | US | claimed |
| EP-2158208-B1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | GILEAD SCIENCES INC (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2008063712-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA | CV THERAPEUTICS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20070299089-A1 | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia | CV THERAPEUTICS, INC. | 2007-12-27 | — | — | US | claimed |
| US-20070265445-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | GILEAD SCIENCES, INC. | 2007-11-15 | — | — | US | claimed |
| US-20070225247-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | GILEAD SCIENCES, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007092372-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-7183264-B2 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-20050175535-A1 | Myocardial perfusion imaging method | CV THERAPEUTICS, INC. | 2005-08-11 | — | — | US | claimed |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-02-26 | — | — | US | claimed |
| EP-1189916-B1 | N-PYRAZOLE A 2A RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2003-12-10 | — | — | EP | claimed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265445-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 5/4885 |
| US-20070299089-A1 | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20070225247-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20160024137-A1 | STABLE SOLID FORMS OF REGADENOSON | CYP2D6, RAB6A, F7 | ADORA2A 462/4885ADORA3 390/4885ADORA2B 309/4885 |
| US-20050175535-A1 | Myocardial perfusion imaging method | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-10144756-B2 | Stable solid forms of regadenoson | CYP2D6, RAB6A, F7 | ADORA2A 462/4885ADORA3 390/4885ADORA2B 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.